Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet ...
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and ...
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a ...
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Gregg Gorniak looks back at DSCSA's ...
Four pillars frame executive dialogue: industry transformation, resilient supply networks, operationalizing policy expectations, and scaling manufacturing capacity/infrastructure to match accelerating ...
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption. In the third and final installment of Pharmaceutical Commerce’s video ...
As pharmaceutical companies move AI into patient access and support operations, most still rely on manual sampling and ...
DSCSA compliance is no longer a live question for most trading partners, but two new work streams, the shift to a 12-digit ...
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes. The complex nature of the pipeline means that equipment ...
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk ...
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates. The Centers for Medicare & Medicaid Services (CMS) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results